Raffi Mark Asadorian
Chief Financial OfficerMr. Raffi Mark Asadorian served as Independent Director of Willow Biosciences Inc. since May 12, 2023 until June 2025. He has been Chief Financial Officer of Phillips 66 Partners GP LLC at Phillips 66 Partners LP since August 16, 2017. Mr. Asadorian has been the Chief Financial Officer of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since August 16, 2017. He served as Consultant of Amyris, Inc. since January 5, 2017. He served as the Chief Financial Officer of Amyris, Inc. since January 6, 2014 until January 4, 2017. He served as the Chief Financial Officer of Unilabs SA from August 2009 to October 6, 2014. He served as Chief Financial Officer and Senior Vice President at PLIVA Pharmaceuticals, Inc. (alternate name, Pliva farmaceutika, dionicko dru?tvo) from 2007 to 2009 and served as its Member of Management Board. He served as a Supervisory Board Member at PLIVA-Lachema a.s. He served with PricewaterhouseCoopers (PwC), where he was a Partner in its Transaction Services (mergers and acquisitions advisory) group in New York. He was responsible for advising on mergers, acquisitions and divestitures for private equity clients and corporate clients in various industries, with a focus in healthcare and pharmaceuticals. From 2001 to 2003, he served with PwC in Zurich, where he led M&A advisory teams for numerous global and large Swiss clients. He held a senior executive finance role at Barr Pharmaceuticals. Mr. Asadorian served as Senior Vice President and Chief Financial Officer of the PLIVA Group. Mr. Asadorian holds a Bachelor of Science in Business Administration in Accounting from Xavier University (USA) and a Master of Business Administration degree from the University of Manchester (U.K.).
Positions
- Company NameTalphera, Inc.Stock CodeTLPHPositionChief Financial Officer
